Enzymatic Dna Synthesis Market Companies
EVONETIX, DNA TWOPOINTO, INC., GENSCRIPT, TELESIS BIO INC., DNA SCRIPT, and others are at the forefront of the reusable launch vehicle sector. Important strategies for reusable launch vehicle companies include developing reusability technologies to enable faster turnaround and lower launch costs, securing government and commercial contracts for consistent revenue, and enhancing efficiency and quality control through vertical manufacturing integration.
List of Key Players in the Market:
- Telesis Bio Inc.
- Evonetix
- Ansa Biotechnologies
- Camena Bioscience
- GenScript
- DNA Script
- Eurofins Scientific
- Synbio Technologies
- DNA TWOPOINTO, INC.
- TWIST BIOSCIENCE
- Elegen Corporation
- Yeasen
- Molecular Assemblies
- GenomeWeb
- Bellatrix Aerospace
Recent News:
- Telesis Bio declared its intention to offer shares of a new series of convertible preferred stock in a private placement through the execution of a convertible preferred stock purchase agreement (the Purchase Agreement) in May 2025. Gibson SOLA, the companies newly released patented next-generation enzymatic synthesis technology, gives clients complete control over their nucleic acid supply chain, safeguards important intellectual property, and preserves data and insights to feed future AI drug discovery models. The Gibson SOLA reagent platform and full suite of tools enables clients to synthesize long, complicated constructions required for research and development of biologics, vaccines, and cell therapies overnight using standard automated liquid handling equipment.
- Enzymatic DNA synthesis pioneer and leader Molecular Assemblies, Inc. announced the opening of its Partnering Program to license Molecular Assemblies' Fully Enzymatic SynthesisTM (FESTM) technology for on-site synthesis in May 2024. Long, accurate, and pure DNA can be produced more quickly thanks to FES technology, which will power a new, quickly developing generation of medicines and diagnostics.
- Molecular Assemblies, Inc., a leader in enzymatic DNA synthesis, and Codexis, Inc., a leading enzyme engineering company that makes synthetic biology possible, announced the signing of a Commercial License and Enzyme Supply Agreement in August 2022. This agreement allows Molecular Assemblies to use an evolved terminal deoxynucleotidyl transferase (TdT) enzyme in their Fully Enzymatic SynthesisTM (or FESTM) technology. In order to promote fully enzymatic DNA synthesis and produce long, precise, and pure oligonucleotides that would spur innovation across numerous industries, the firms worked together to develop this supercharged TdT enzyme.